Key takeaways Wegovy (semaglutide) is a GLP-1 drug that is FDA approved for weight loss, cardiovascular risk reduction, and liver disease treatment
Our providers track progress and adjust your plan for consistent, healthy results
Key Benefits Marked reduction in body weight in clinical studies, with high-impact results in obesity
The known risks associated with these medicines are reflected in their FDA-approved product labeling which, collectively, FDA has reviewed more than 40 times and are discussed in textbooks, treatment guidelines and journals. Novo Nordisk updates product labels in cooperation with the FDA and consistent with federal regulations to reflect the most current understanding of the safety and efficacy profile of our medicines, said Flavia Brakling, a spokesperson for the company
Himmerich H (2025) Glucagon-like-peptide-1-Rezeptoragonisten: eine neue pharmakologische Behandlungsoption fr psychiatrische Erkrankungen
GLP-1 and Muscle Loss: What the Research Shows GLP-1 and muscle loss What studies show about lean-mass loss on GLP-1s and how to protect muscle
